In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Supernus Pharmaceuticals (SUPN), with a price target of $63. The company’s shares closed yesterday at $36.96.
Rivkind Koffler noted:
“We reiterate our Buy rating as we like the company’s CNS pipeline in ADHD. The next catalyst in the stock should be the read-out of the SPN-810 pediatric trials in 2H:19, which we view as risky to our Buy rating and $63 PT, but it may act as a clearing event for the stock.”
According to TipRanks.com, Koffler is a 3-star analyst with an average return of 1.0% and a 39.9% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.
Supernus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $61.50.
See today’s analyst top recommended stocks >>
Based on Supernus Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $25.89 million. In comparison, last year the company had a net profit of $26.35 million.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SUPN in relation to earlier this year. Last month, John Siebert, a Director at SUPN bought 10,000 shares for a total of $91,300.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.
